The latest biotech news

News and Trends 1 Aug 2022

BioMed X Institute and Merck start new oncology research project

BioMed X, a German independent research institute, has started a new research project ‘Extrachromosomal DNA in Cancer’ (EDC) in collaboration with the Healthcare Business of Merck KGaA, Darmstadt, Germany. The main objective of this research group is to develop an atlas of extrachromosomal DNA (ecDNA) in human cancer tissues and trace back the mechanisms of […]

August 1, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 1 Aug 2022

Zenas BioPharma gets Chinese approval for thyroid eye disease treatment study

Zenas BioPharma has received approval of its Investigational New Drug (IND) application from the National Medical Products Administration (NMPA) of China to start a phase 1/2 clinical study of ZB001 to treat thyroid eye disease (TED). The main objective of the study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZB001. About […]

August 1, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 1 Aug 2022

Clinical hold on trial for colorectal cancer drug lifted by FDA

A clinical hold has been lifted by the US Food and Drug Administration (FDA) on a trial for a treatment for colorectal cancer after changes were made by the company responsible. Belgium-based Celyad Oncology SA is a clinical biotech company focused on finding and developing chimeric antigen receptor T cell (CAR T) therapies for cancer. […]

August 1, 2022 - 2 minutesmins - By Liza Laws

More News! 29 Jul 2022

Cancer patients enrolled on study to predict immunotherapy response

An observational study has started enrolling patients with advanced/metastatic non-small cell lung cancer (NSCLC). Florida-based Nilogen Oncosystems made the announcement today (July 29) that those who are receiving immune checkpoint inhibitors in the standard of care will be registered for the study. Using advanced artificial intelligence and machine learning algorithms to discover biomarker signatures as […]

July 29, 2022 - 3 minutesmins - By Liza Laws

News and Trends 29 Jul 2022

VerImmune raises $2.5M to develop virus-inspired particle immunotherapies

VerImmune, Inc., a U.S. biotech company developing new therapeutic modalities that aim to redirect the body’s pre-existing immunity toward cancer, has obtained $2.5 million in seed funding. The round was led by SeedFolio, a seed series venture capital firm. The round also included participation from U.S. and global investment venture firms such as Ulu Ventures, […]

July 29, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 29 Jul 2022

Sarepta looks for quick approval for Duchenne muscular dystrophy gene therapy treatment

U.S. company Sarepta Therapeutics, Inc. said it intends to submit a Biologics License Application (BLA) seeking accelerated approval for SRP-9001 (delandistrogene moxeparvovec) to treat ambulant individuals with Duchenne muscular dystrophy. SRP-9001 is an investigational gene therapy for Duchenne being developed in partnership with Roche. “We are delighted to confirm that based on the feedback we […]

July 29, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 29 Jul 2022

Biotech startup Novasenta raises $40M to advance novel cancer therapeutics

Novasenta Inc., a U.S. startup biotech company focused on the discovery and validation of novel targets to develop cancer therapies, has completed $40 million in Series A financing. The round was led by UPMC Enterprises. The funding will allow Novasenta to advance its pipeline of antibody-based therapeutics and expand its computational platforms for target discovery, […]

July 29, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 29 Jul 2022

Commercial personalized cancer cell profile developed in Taiwan

Patients with stage 2 solid tumors could benefit from the world’s first commercial personalized cancer cell profiling, developed in Taiwan. Taipei-based CancerFree Biotech Ltd has developed the technology that will help stage 2 patients and above by shortening the selection process. The technology will be showcasing at US Bio 2022. This is the world’s first […]

July 29, 2022 - 3 minutesmins - By Liza Laws

News and Trends 29 Jul 2022

Beyond Biotech podcast 7: World Hepatitis Day

This week’s podcast features three interviews related to hepatitis. Our guests are Ahmed Elsharkawy, consultant transplant hepatologist and honorary senior clinical lecturer at the University of Birmingham in the UK; Ziv Ben-Ari, director of the Liver Diseases Center at the Sheba Medical Center in Israel, and James McIlroy, chief executive officer at EnteroBiotix. World Hepatitis […]

July 29, 2022

News and Trends 28 Jul 2022

AGC Biologics announces gene therapy partnership with Altheia Science

A new development partnership between gene therapy company Altheia Sciences, which pioneers cell and gene treatments, and AGC Biologics, will look at strategies to treat autoimmune disease and cancer. Specifically, the partnership will help advance development of autoimmunity treatments, focused on modulating PD-L1 expression in patients’ hematopoietic stem and progenitor cells, into clinical testing. PD-L1 […]

July 28, 2022 - 2 minutesmins - By Liza Laws

News and Trends 28 Jul 2022

Mission Bio launches new cancer assay

Life sciences company Mission Bio, Inc. has announced the availability of the industry’s first assay capable of determining measurable residual disease (MRD) in cancer down to the level of individual cells. Mission Bio said this heralds a new era for the understanding of disease progression. The single-cell multi-omics MRD (scMRD) assay for acute myeloid leukemia […]

July 28, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 28 Jul 2022

Biogen’s New Drug Application for first treatment of rare form of neurological disease accepted by FDA

A drug to target a rare genetic form of a neurological disease that affects the nerve cells, leading to the loss of everyday functions, could be the first of its kind available if approved. The US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) from Massachusetts-based Biogen Inc. for tofersen, an […]

July 28, 2022 - 4 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

BioMed X Institute and Merck start new oncology research project

Zenas BioPharma gets Chinese approval for thyroid eye disease treatment study

Clinical hold on trial for colorectal cancer drug lifted by FDA

Cancer patients enrolled on study to predict immunotherapy response

VerImmune raises $2.5M to develop virus-inspired particle immunotherapies

Sarepta looks for quick approval for Duchenne muscular dystrophy gene therapy treatment

Biotech startup Novasenta raises $40M to advance novel cancer therapeutics

Commercial personalized cancer cell profile developed in Taiwan

Beyond Biotech podcast 7: World Hepatitis Day

AGC Biologics announces gene therapy partnership with Altheia Science

Mission Bio launches new cancer assay

Biogen’s New Drug Application for first treatment of rare form of neurological disease accepted by FDA

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!